Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: “The clinical validation results of Ataraxis Breast–the first AI-native prognostic/predictive test for breast cancer patients are impressive.”

NEW YORK – Ataraxis AI is developing artificial intelligence-driven digital pathology tests that it believes may provide faster, more accurate, and more cost-effective answers to clinical questions about cancer patients' outcomes and recurrences than traditional molecular tests on the market.

Startup Ataraxis, which emerged from stealth Thursday, has developed a model that can predict the risk severity of breast cancer up to 30% more accurately than current tests.

Ataraxis AI, backed by $4M in seed funding, emerges from stealth and launches Ataraxis Breast — the world’s first AI-native breast cancer prognostic test, and Kestrel — a state-of-the-art AI foundation model for digital pathology.

In this NeurIPS 2024 Workshop paper, we demonstrate the importance of hyperparameter tuning in training digital pathology AI foundation models.

We describe the development and validation of Ataraxis Breast, the first AI-native breast cancer prognostication tool.